These advances aim to exploit the non-canonical roles of Nrf2 in the regulation of post-transcriptional RNA metabolism, particularly relevant in ALS, where mislocalization and aggregation of RBPs (e.g., TDP-43, FUS) are central to pathogenesis [125]. The gene discussed is FUS; the disease is amyotrophic lateral sclerosis.